Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component

Roberto Moretto; Federica Morano; Elena Ongaro; Daniele Rossini; Filippo Pietrantonio; Mariaelena Casagrande; Carlotta Antoniotti; Salvatore Corallo; Federica Marmorino; Francesco Cortiula; Federico Nichetti; Beatrice Borelli; Gemma Zucchelli; Alessandra Boccaccino; Gianluca Masi; Filippo de Braud; Alfredo Falcone; Chiara Cremolini

doi:10.1016/j.clcc.2019.02.007

Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component

Roberto Moretto, Federica Morano, Elena Ongaro, Daniele Rossini, Filippo Pietrantonio, Mariaelena Casagrande, Carlotta Antoniotti, Salvatore Corallo, Federica Marmorino, Francesco Cortiula, Federico Nichetti, Beatrice Borelli, Gemma Zucchelli, Alessandra Boccaccino, Gianluca Masi, Filippo de Braud, Alfredo Falcone, Chiara Cremolini

Research output: Contribution to journal › Article › peer-review

Abstract

Adenocarcinoma with mucinous histology or mucinous component are histologic subtypes of metastatic colorectal cancers (mCRCs) with limited benefit from cytotoxic agents. Their sensitivity to anti-epithelial growth factor receptors (EGFRs) is not clear. We retrospectively identified patients with RAS/BRAF wild-type mCRC treated with anti-EGFRs. Our findings suggest no benefit from anti-EGFRs in mCRC with mucinous histology or mucinous component, irrespective of sidedness.

Original language	English
Pages (from-to)	116-124
Number of pages	9
Journal	Clinical Colorectal Cancer
Volume	18
Issue number	2
DOIs	https://doi.org/10.1016/j.clcc.2019.02.007
Publication status	Published - Jun 2019

Keywords

Adenocarcinoma with mucinous component
Anti-EGFR monoclonal antibodies
Metastatic colorectal cancer
Mucinous adenocarcinoma
RAS and BRAF wild-type mCRC

ASJC Scopus subject areas

Oncology
Gastroenterology

Access to Document

10.1016/j.clcc.2019.02.007

Cite this

Moretto, R., Morano, F., Ongaro, E., Rossini, D., Pietrantonio, F., Casagrande, M., Antoniotti, C., Corallo, S., Marmorino, F., Cortiula, F., Nichetti, F., Borelli, B., Zucchelli, G., Boccaccino, A., Masi, G., de Braud, F., Falcone, A., & Cremolini, C. (2019). Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component. Clinical Colorectal Cancer, 18(2), 116-124. https://doi.org/10.1016/j.clcc.2019.02.007

Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component. / Moretto, Roberto; Morano, Federica; Ongaro, Elena; Rossini, Daniele; Pietrantonio, Filippo; Casagrande, Mariaelena; Antoniotti, Carlotta; Corallo, Salvatore; Marmorino, Federica; Cortiula, Francesco; Nichetti, Federico; Borelli, Beatrice; Zucchelli, Gemma; Boccaccino, Alessandra; Masi, Gianluca ; de Braud, Filippo ; Falcone, Alfredo; Cremolini, Chiara.

In: Clinical Colorectal Cancer, Vol. 18, No. 2, 06.2019, p. 116-124.

Research output: Contribution to journal › Article › peer-review

Moretto, R, Morano, F, Ongaro, E, Rossini, D, Pietrantonio, F, Casagrande, M, Antoniotti, C, Corallo, S, Marmorino, F, Cortiula, F, Nichetti, F, Borelli, B, Zucchelli, G, Boccaccino, A, Masi, G , de Braud, F , Falcone, A & Cremolini, C 2019, 'Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component', Clinical Colorectal Cancer, vol. 18, no. 2, pp. 116-124. https://doi.org/10.1016/j.clcc.2019.02.007

Moretto, Roberto ; Morano, Federica ; Ongaro, Elena ; Rossini, Daniele ; Pietrantonio, Filippo ; Casagrande, Mariaelena ; Antoniotti, Carlotta ; Corallo, Salvatore ; Marmorino, Federica ; Cortiula, Francesco ; Nichetti, Federico ; Borelli, Beatrice ; Zucchelli, Gemma ; Boccaccino, Alessandra ; Masi, Gianluca ; de Braud, Filippo ; Falcone, Alfredo ; Cremolini, Chiara. / Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component. In: Clinical Colorectal Cancer. 2019 ; Vol. 18, No. 2. pp. 116-124.

@article{dd22f906690749cc8284f712b48fb278,

title = "Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component",

abstract = "Adenocarcinoma with mucinous histology or mucinous component are histologic subtypes of metastatic colorectal cancers (mCRCs) with limited benefit from cytotoxic agents. Their sensitivity to anti-epithelial growth factor receptors (EGFRs) is not clear. We retrospectively identified patients with RAS/BRAF wild-type mCRC treated with anti-EGFRs. Our findings suggest no benefit from anti-EGFRs in mCRC with mucinous histology or mucinous component, irrespective of sidedness.",

keywords = "Adenocarcinoma with mucinous component, Anti-EGFR monoclonal antibodies, Metastatic colorectal cancer, Mucinous adenocarcinoma, RAS and BRAF wild-type mCRC",

author = "Roberto Moretto and Federica Morano and Elena Ongaro and Daniele Rossini and Filippo Pietrantonio and Mariaelena Casagrande and Carlotta Antoniotti and Salvatore Corallo and Federica Marmorino and Francesco Cortiula and Federico Nichetti and Beatrice Borelli and Gemma Zucchelli and Alessandra Boccaccino and Gianluca Masi and {de Braud}, Filippo and Alfredo Falcone and Chiara Cremolini",

year = "2019",

month = jun,

doi = "10.1016/j.clcc.2019.02.007",

language = "English",

volume = "18",

pages = "116--124",

journal = "Clinical Colorectal Cancer",

issn = "1533-0028",

publisher = "Elsevier Inc.",

number = "2",

}

TY - JOUR

T1 - Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component

AU - Moretto, Roberto

AU - Morano, Federica

AU - Ongaro, Elena

AU - Rossini, Daniele

AU - Pietrantonio, Filippo

AU - Casagrande, Mariaelena

AU - Antoniotti, Carlotta

AU - Corallo, Salvatore

AU - Marmorino, Federica

AU - Cortiula, Francesco

AU - Nichetti, Federico

AU - Borelli, Beatrice

AU - Zucchelli, Gemma

AU - Boccaccino, Alessandra

AU - Masi, Gianluca

AU - de Braud, Filippo

AU - Falcone, Alfredo

AU - Cremolini, Chiara

PY - 2019/6

Y1 - 2019/6

N2 - Adenocarcinoma with mucinous histology or mucinous component are histologic subtypes of metastatic colorectal cancers (mCRCs) with limited benefit from cytotoxic agents. Their sensitivity to anti-epithelial growth factor receptors (EGFRs) is not clear. We retrospectively identified patients with RAS/BRAF wild-type mCRC treated with anti-EGFRs. Our findings suggest no benefit from anti-EGFRs in mCRC with mucinous histology or mucinous component, irrespective of sidedness.

AB - Adenocarcinoma with mucinous histology or mucinous component are histologic subtypes of metastatic colorectal cancers (mCRCs) with limited benefit from cytotoxic agents. Their sensitivity to anti-epithelial growth factor receptors (EGFRs) is not clear. We retrospectively identified patients with RAS/BRAF wild-type mCRC treated with anti-EGFRs. Our findings suggest no benefit from anti-EGFRs in mCRC with mucinous histology or mucinous component, irrespective of sidedness.

KW - Adenocarcinoma with mucinous component

KW - Anti-EGFR monoclonal antibodies

KW - Metastatic colorectal cancer

KW - Mucinous adenocarcinoma

KW - RAS and BRAF wild-type mCRC

UR - http://www.scopus.com/inward/record.url?scp=85063687686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063687686&partnerID=8YFLogxK

U2 - 10.1016/j.clcc.2019.02.007

DO - 10.1016/j.clcc.2019.02.007

M3 - Article

C2 - 30952563

AN - SCOPUS:85063687686

VL - 18

SP - 116

EP - 124

JO - Clinical Colorectal Cancer

JF - Clinical Colorectal Cancer

SN - 1533-0028

IS - 2

ER -

Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this